Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Omalizumab Kit ELISA

Ce kit ELISA Humain, Souris et Rat Omalizumab est un kit ELISA Colorimetric conçu pour quantifier Humain, Souris et Rat Omalizumab.
N° du produit ABIN4886395

Aperçu rapide pour Omalizumab Kit ELISA (ABIN4886395)

Antigène

Omalizumab

Reactivité

Humain, Souris, Rat

Méthode de détection

Colorimetric

Type de méthode

Sandwich ELISA

Gamme de detection

1.56-50 ng/mL

Application

ELISA

Type d'échantillon

Plasma, Serum
  • Seuil minimal de détection

    1.56 ng/mL

    Fonction

    Quantification of Omalizumab in biological matrices

    Analytical Method

    Quantitative

    Specificité

    Omalizumab (Xolair)

    Réactivité croisée (Details)

    hIgG1, Rituximab, and Infliximab prepared at 250 ng/mL were assayed and exhibited no cross-reactivity or interference.

    Ingrédients

    Coated microtiter plate, 96 wells
    Calibrator diluent. - 1.8ml
    Calibrator 12ul
    10X wash buffer - 25ml
    Assay buffer - 50ml
    1000X detection reagent - 17ul
    TMB - 12ml
    TMB stop solution - 12ml
    Plate sealers - 3

    Matériel non inclus

    Precision pipettes calibrated to deliver 5-1000μL
    Multi-channel pipette calibrated to deliver 50-200μL
    Plate shaker
    Disposable tips
    Vortex-Mixer
    Distilled or de-ionized water
    Microplate reader capable of reading 450nm with background subtrac
  • Indications d'application

    Optimal working dilution should be determined by the investigator.

    Volume d'échantillon

    15 μL

    Durée du test

    2.5 h

    Plaque

    Pre-coated

    Protocole

    The Omalizumab ELISA kit is designed to measure free Omalizumab with high specificity and sensitivity . This assay employs the sandwich enzyme immunoassay technique. A precoated anti-Omalizumab 96 well plate is provided. Calibrator, quality control samples and test samples are pipetted into the appropriate wells. Omalizumab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, enzyme linked detection antibody is added to the wells. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Omalizumab present in test samples and the concentration is calculated from the standard series.

    Préparation des réactifs

    Prepare only the appropriate amount of required reagent on the day of use. Store all reagents as per instructions stated on the label. 1. Wash Buffer (1X) Preparation: Dilute wash buffer concentrate with ultra-pure water 1/10 before use (for example add 20 mL concentrate to 180 mL ultra-pure water). Mix well. 2. Detection Reagent (1X) Preparation: Dilute detection reagent with assay buffer 1/1000 before use (for example add 11 μL concentrate to 11 mL of assay buffer). Mix well. 3. Preparation of Calibrators: Prepare calibrators with concentrations ranging from 2,500 ng/mL to 78 ng/mL. The following is an example calibrator curve.

    Prélèvement de l'échantillon

    This kit is compatible with EDTA-plasma, heparinplasma and serum samples. Samples can be stored at or below -20 °C for up to 1 year.

    Préparation de l'échantillon

    Dilute calibrators and test samples 1/50 with assay buffer (for example add 5μL of prepared calibrator or sample to 245μL of assay buffer). Mix well. Do not store diluted samples.

    Procédure de l'essai

    This assay employs the sandwich enzyme immunoassay technique. Anti- Omalizumab is coated onto a 96 well microplate. Calibrator and test samples are pipetted into the appropriate wells. Omalizumab present in biological matrices is bound by the immobilized anti- Omalizumab antibody. After washing away any unbound substances, enzyme linked anti- Omalizumab antibody is added to the wells. This antibody is developed and purified specifically against Xolair® (domain residing in Fc portion of the Xolair® molecule). The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Omalizumab present in test samples. The color development is stopped and the intensity of the color is measured

    Calcul des résultats

    1. Construct a standard curve by plotting the absorbance obtained from each standard against concentration. Use a 4 or 5 parameter curve fit. Alternatively a log-log curve fit may be used. 2. The concentration of the unknowns can be read directly from this standard curve using the absorbance value for each sample. 3. Any sample undiluted or diluted still reading greater than the highest standard should be diluted appropriately with calibrator diluent and retested. If the samples have been diluted, the concentration determined from the standard curve must be multiplied by the dilution factor.

    Précision du teste

    Precision: Precision was determined by analyzing 6 replicates of serum spiked with 500ng/mL Omalizumab on 6 different occasions. Intra-assay coefficient of variation (CV) < 10%. Inter-assay CV < 10%.

    Recovery: 250 ng/mL of Omalizumab was spiked in 10 lots of human serum. Recovery ranges are from 95-112% with an average recovery of 104%.

    Restrictions

    For Research Use only
  • Agent conservateur

    Without preservative

    Précaution d'utilisation

    Read manual completely before beginning

    Stock

    -20 °C

    Stockage commentaire

    Store kit components at -20°C unless specified otherwise. DO NOT USE past kit expiration date. Some vials contain a small amount of reagents. Spin tubes on pulse setting prior to opening.

    Date de péremption

    12 months
  • Antigène

    Omalizumab

    Classe de substances

    Antibody

    Sujet

    Omalizumab (Xolair®) is a recombinant DNA-derived humanized IgG1κ monoclonal antibody that binds human immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma and Chronic Idiopathic Urticaria (CIU). Omalizumab inhibits the binding of IgE to IgE receptor (FcεRI) on the surface of mast cells and basophils thereby limiting the release of mediators of the allergic response from the FcεRI bearing cells

    ID gène

    3497
Vous êtes ici:
Chat with us!